Abvc Biopharma (ABVC) Non Operating Interest Expenses (2010 - 2026)

Abvc Biopharma (ABVC) has reported Non Operating Interest Expenses for 14 consecutive years, with $42323.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 67.3% year-over-year to $42323.0; the trailing twelve-month figure through Jun 2026 stood at $155210.0 (down 80.34% YoY), and the FY2025 full-year result was $415890.0, down 49.64% from the prior year.
• Non Operating Interest Expenses declined to $42323.0 in Q2 2026 per ABVC's latest filing, from $49377.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $1.2 million in Q3 2023 and bottomed at -$76368.0 in Q4 2023.
• Historically, Non Operating Interest Expenses has averaged $163396.0 across 5 years, with a median of $120644.0 in 2022.
• The widest YoY moves for Non Operating Interest Expenses: up 863.07% in 2023, down 156.8% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $134461.0 in 2022, then sank by 156.8% to -$76368.0 in 2023, then jumped by 383.78% to $216715.0 in 2024, then tumbled by 84.98% to $32551.0 in 2025, then soared by 30.02% to $42323.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $42323.0, $49377.0, and $32551.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.